114 related articles for article (PubMed ID: 9704729)
1. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer.
Christodoulou CV; Ferry DR; Fyfe DW; Young A; Doran J; Sheehan TM; Eliopoulos A; Hale K; Baumgart J; Sass G; Kerr DJ
J Clin Oncol; 1998 Aug; 16(8):2761-9. PubMed ID: 9704729
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
4. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
[TBL] [Abstract][Full Text] [Related]
6. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
Rinaldi DA; Burris HA; Dorr FA; Woodworth JR; Kuhn JG; Eckardt JR; Rodriguez G; Corso SW; Fields SM; Langley C
J Clin Oncol; 1995 Nov; 13(11):2842-50. PubMed ID: 7595747
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Villalona-Calero MA; Baker SD; Hammond L; Aylesworth C; Eckhardt SG; Kraynak M; Fram R; Fischkoff S; Velagapudi R; Toppmeyer D; Razvillas B; Jakimowicz K; Von Hoff DD; Rowinsky E
J Clin Oncol; 1998 Aug; 16(8):2770-9. PubMed ID: 9704730
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
17. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
19. Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane.
Schilling T; Keppler KB; Heim ME; Niebch G; Dietzfelbinger H; Rastetter J; Hanauske AR
Invest New Drugs; 1996; 13(4):327-32. PubMed ID: 8824351
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
